Usefulness of Beta Blockers in High-Risk Patients After Myocardial Infarction in Conjunction With Captopril and/or Valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] Trial)

American Journal of Cardiology

Volumn 104, Issue 2, 2009, Pages 151-157

  Califf, Robert M ^a   Lokhnygina, Yuliya ^b   Velazquez, Eric J ^b   McMurray, John J V ^c   Leimberger, Jeffrey D ^b   Lewis, Eldrin F ^d   Diaz, Rafael ^e   Murin, Jan ^f   Pfeffer, Marc A ^d  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c WESTERN INFIRMARY   (United Kingdom)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e Etudios Cardiologica Latin America Rosario   (Argentina)

^f UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; VALSARTAN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; FEMALE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; SYSTOLIC DYSFUNCTION; TREATMENT OUTCOME;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CAPTOPRIL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 67649311597     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.03.020     Document Type: Article

References (13)

1. Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.L., Kober L., Maggioni A.P., Solomon S.D., Swedberg K., Van de Werf F., White H., Leimberger J.D., Henis M., Edwards S., Zelenkofske S., Sellers M.A., Califf R.M., and the VALIANT Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
2. Pfeffer M.A., McMurray J., Leizorovicz A., Maggioni A.P., Rouleau J.L., Van De Werf F., Henis M., Neuhart E., Gallo P., Edwards S., Sellers M.A., Velazquez E., and Califf R. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 140 (2000) 727-750
3. Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., Olofsson B., Ostergren J., Yusuf S., Pocock S., and CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
4. Cohn J.N., Tognoni G., and Valsartan Heart Failure Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
5. Lee K.L., McNeer J.F., Starmer C.F., Harris P.J., and Rosati R.A. Clinical judgement and statistics. Lessons from a simulated randomized trial in coronary artery disease. Circulation 61 (1980) 508-515
6. ISIS-2 Collaboration Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected myocardial infarction. Lancet 332 (1988) 349-360
7. Yusuf S., Wittes J., Probstfield J., and Tyroler H.A. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 266 (1991) 93-98
8. Pfisterer M., Cox J.L., Granger C.B., Brener S.J., Naylor C.D., Califf R.M., van de Werf F., Stebbins A.L., Lee K.L., Topol E.J., and Armstrong P.W. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 32 (1998) 634-640
9. Chen Z.M., Pan H.C., Chen Y.P., Peto R., Collins R., Jiang L.X., Xie J.X., Liu L.S., and COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1622-1632
10. Reed S.D., McMurray J.J.V., Velazquez E.J., Schulman K.A., Califf R.M., Kober L., Maggioni A.P., Van de Werf F., White H.D., Diaz R., Mareev V., Murin J., and VALIANT Committees and Investigators. Geographic variation in the treatment of acute myocardial infarction in the VALIANT trial. Am Heart J 152 (2006) 500-508
11. Chen J., Radford M.J., Wang Y., Marciniak T.A., and Krumholz H.M. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 37 (2001) 1950-1956
12. Krumholz H.M., Radford M.J., Wang Y., Chen J., Heiat A., and Marciniak T.A. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 280 (1998) 623-629
13. ONTARGET Investigators, Yusuf S., Teo K.K., Pogue J., Dyal L., Copland I., Schumacher H., Dagenais G., Sleight P., and Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559